接受当代治疗的FLT3内部串联重复突变初诊急性髓系白血病患者结局改善:重新审视欧洲白血病网不良风险分类
该研究回顾性分析了2012年1月至2020年1月在一家大型学术医学中心连续诊治的1576例初诊急性髓系白血病患者,其中1438例(91%)接受了FLT3突变分子检测,304例(21%)存在FLT3突变,包括17%的FLT3-ITD突变。研究显示,FLT3-ITD高等位基因比率且NPM1野生型患者的生存较其他欧洲白血病网不良风险疾病显著改善;在多变量Cox比例风险模型中,FLT3突变对接受强化或低强度诱导方案的患者无预后意义;异基因造血干细胞移植似乎改善FLT3突变患者的生存,尤其是欧洲白血病网不良风险者。
要点
- 1576例初诊AML中1438例(91%)接受FLT3检测,304例(21%)有FLT3突变,17%为FLT3-ITD。
- FLT3-ITD高AR且NPM1野生型患者生存较其他ELN不良风险疾病显著改善。
- 多变量Cox模型中FLT3突变对强化或低强度诱导患者无预后意义;异基因SCT在CR1似乎改善生存。
核心结论
- 当代治疗背景下FLT3突变的预后影响正在改变,适当联合诱导治疗、靶向药物和异基因造血干细胞移植可改善结局。
研究设计与样本
- 回顾性分析2012年1月至2020年1月在一家大型学术医学中心连续诊治的1576例初诊急性髓系白血病患者,其中1438例(91%)接受了FLT3突变分子检测。
主要发现
- 1438例接受FLT3检测的患者中304例(21%)存在FLT3突变,包括17%的FLT3-ITD突变。
- FLT3-ITD高等位基因比率且NPM1野生型患者的生存较其他欧洲白血病网不良风险疾病显著改善。
- 在接受强化或低强度诱导方案患者的多变量Cox比例风险模型中,FLT3突变无预后意义。
- 异基因造血干细胞移植用于FLT3突变患者首次完全缓解(CR1)似乎改善生存,尤其是欧洲白血病网不良风险疾病患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutations in fms-like tyrosine kinase 3 (FLT3) gene are common genomic alterations in acute myeloid leukemia (AML). FLT3 internal tandem duplication mutations (FLT3-ITD) have consistently been shown to be adversely prognostic, particularly those with high allelic ratio (AR). Current AML treatment strategies, including high dose cytarabine, purine analogs, FLT3 inhibitors (FLT3i), and with or without allogeneic stem cell transplant (SCT) have been shown to improve the outcomes in patients with FLT3 mutations. We analyzed a consecutive cohort of newly diagnosed patients with AML treated at a large academic medical center from January 2012 to January 2020. A total of 1576 patients with a new diagnosis of AML were reviewed. Among these, 1438 (91%) had molecular testing for FLT3 mutations and 21% (304/1438) had an FLT3 mutation, including 17% with an FLT3-ITD mutation. We show that FLT3-ITD high AR with NPM1 wild-type have significantly improved survival compared with other European LeukemiaNet (ELN) adverse risk disease. In multivariable cox proportional hazards model of patients receiving intensive or low-intensity induction regimens, FLT3 mutations did not have prognostic significance. The use of allogeneic SCT in CR1 for patients with FLT3 mutations appears to improve survival, particularly in those with ELN adverse risk disease. Overall, this data highlights the changing prognostic impact of FLT3 mutations in a contemporary era with appropriate use of induction therapy combined with targeted agents and allogenic SCT.
引用
- Reville PK, Sasaki K, Kantarjian HM, et al. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022. PMID: 34981570. doi:10.1002/ajh.26451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。